Indeed, a recent study reported that the combined in vitro treatment with an ADAM17 inhibitor and cisplatin showed enhanced cytotoxicity in ovarian cancer spheroids in comparison with cisplatin monotherapy, thus proposing ADAM17 as an interesting target for combinatorial treatments [57]. This evidence concerns the gene ADAM17 and ovarian cancer.